Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think the “market” wants those registered shares first. Dont want to use that lawsuit tool just yet until they extract as much as they can. Its a long road to commercialization with the next cycle in the “fair and balanced market” being to sell into the next pump.
ANVS will need to raise a lot of money for another phase 3. Many CEO’s and boards cut their losses, grab all their free shares and partner allowing the new partner to take over the final trial design and commercialization. This could be the just of whats playing out as we speak.
No shares down here, when will the MM’s move this up? Up $1, down .75 isnt shaking the tree like it use to, time to get this into the $13-$15 range imo or $1.30-$1.50 range for us patient longs.
So…, who is the big buyer of Chromadex? The timing of you “guys” being here “holding big bags” is for a reason, so who is it?
Yup! Cant wait for the May 13 nothing burger date to pass. Seriously. This is a pathetic freak show parading advertisements meant to scare unknowing investors. I dont know how many people asked e about the lawsuits. Ridiculous.
Yes. I could see OTC in 5 years once blarcasamine is approved in multiple countries for Alzheimer’s, PD/PDD, and a few rare diseases. With these vulnerable populations covered, phase 4 OLE’s still rolling, one would have to ask themself why wouldnt the FDA grant this drug OTC status?
Once the MJFF, Rett.org, RAM, Alzheimer’s Association (yeah right) and others are “unleashed” and share the “good news” word will get out. Maybe throw in a year of Major conference “releases”, coupled with Amazons powerful algorithm marketing tools and the pharmaceutical “middlemen” are done.
All just my opinion but I did predict Amazon was a possibility coupled with video conferencing your doctor in hard to reach places and Dr Missling recently mentioned Amazon.
Martha Martha!
JJ I agree with your reply. Anavex is not going to market Blarcasamine as it doesnt have the expertise but what they do have is the wherewithal/expertise to get the drug approved and will imo.
These are difference times, I dont think our drug will be hard for a partner to market for Alz (PD/PDD off label) once it gets approved. This isnt a drug needing to be administered in a clinical setting and doesnt come with the black box warnings and AE’s. This coinciding with the new Alz early detection tests that are surfacing in the market place which will benefit our prophylactic conceptualization. If Dr M has manufacturing broken out I think we are looking at possibly even partnering with amazon for delivery which he has also stated now on the record.
As for rare diseases once we are approved the foundations will spread the news like wildfire and Dr.’s will not need to know about our drug, just give it too them initially and have a few follow ups, the rest will again come in the mail. I think Dr’s and middlemen marketers are stuck in pill pilfering, jabland and office setting visits. Thats all old fashioned once blarcasamine gets approved. I read somewhere AI has even become more efficient than nurses in following medication prescribing and avoiding complications from mistakes. Sad but inevitable.
Enough rambling from my tiny red so(lo)ap box.
Cheers
Lol, TRUTH! Thanks for the great chuckle today Steady!
Plexrec our drug activates our bodies own immune response to various illnesses. It works so far upstream that they still arent sure of all the benefits.
If its changing and is able to alter Rett Syndrome, PDD, mild to moderate Alzheimer's than its only common sense, with our safety, to give the drug earlier in the pathology of the disease and expect it to help prevent the onset of the disease. Not only that but improve sleep disturbances, gait, hand eye coordination etc. Dr. Missling has said as much multiple times that we will one take this like we take aspirin.
Good things, especially in CNS, take a lot of time.
“I suspect that this was all fairly planned. They drove the price down to force the Russell 2000 funds to sell some shares.”
Wow! I know this was mentioned a week or two ago but never thought about applying this to Anvs. Is this possibly applicable? A double whammy bear raid?
Hmmmm.
“Retts is not an emergency, Parkinsons is not an emergency. AD is an emergency.”
Tell that to the parents of Rett patients or for that matter to MJFox. Its ALL an emergency. A little girl going into multiple seizures a day, an adult doing the same or walking around looking to escape in the middle of the night, or a forgetful loved one cursing at you when they dont even know your name, which is the worst? How are all 3 not emergencies? All 3 keep the caretakers/loved at home and up all hours of the. night.
Dr Missling is going for prophylactic use in all 3 and more, just a matter of time.
Looks like they are comin for your $5.51 shares.
OAN 2 million share registration at $5 isnt even goong to keep the doors open let alone pay for another ph 3. My guess is when the larger whales get what they want the price will go up. Maybe these 2 million are an “appetizer”.
Wednesday through Monday is the way of the biotech raiders. Great timing…, I say no, its a crafty game of shock and awe for the thieves. A transfer of wealth if you will by a band of greedy misfits. Any stumble, I mean ANY in the way they release their results and the company’s shareholders get max pain. Looks like they want those 2 million shares the CEO recently filed for dirt cheap. It happens to the best and the worst of them.
“ With the conditional approval, I would have every patient have treatment results reported in a Phase 4 and that too could be the basis for making the conditional approval into a full approval.”
Especially is you apply AI to the process which Anavex has done for many years. I dont think the KEM analysis we use is as powerful as the latest AI but then again what do I know.
Anyway, LETS DO THIS!
Ouch. I barely missed it his one. I was thinking of dipping a toe recently in the $8-$10 range and glad I didnt chase it on their financing announcement. In hindsight it seems a bit smarmy on the surface announcing a financing round a day or two before releasing data when management knew how the market was going to react. Its an evil necessity but financing young biotechs is as brutal as it gets.
With a second phase 3 needed this company is in for a really long haul.
I had to give you a thumbs up boi, even though I dont read his/her posts anymore, because you speak the truth.
Power the Anvs board has the filings. They appear to be favorable towards the company and the timing of the data release is a primer. I pray they do not have any hiccups in their data.
So Annovis just inked a deal to raise funds right before a release of ph 3 data and the soars? Normally dilution causes a stock to tank.
I hope they have solid data and the manipulators transferring wealth are not given an opportunity to crash the stock….for any reason.
Whats the skinny George? No need to download another site to tell us much of what we already know.
“Increased statistical power of EEG/ERP biomarkers to help minimize trial size and cost • Streamlined regulatory process for trials leveraging the EEG/ERP biomarkers”
https://erpbiomarkers.org/
Seems to me this kind of consortium would help call the bluff of a company trying to stretch out its so called failures. Spending 2+ years in a co sortium figuring out specific disease characteristics and measuring metrics is advancing medicine not delaying. All this bei g said Im beginning to believe the Schizophrenia trial could advance to a new stage rather quickly with these new qualifying biomarker tools.
This company is a complete fraud or a grand slam, cant be both or any where in the middle imo and partnerships like this only add to the strength and integrity if you ask me. This is leading, not following the herd off the cliff thinking. Im sure all companies involved are keeping a close eye on trial design and results of our Schizophrenia trial. Our trials keep getting stronger and stronger with time.
Anyone have the new institutional holding numbers due out yesterday?
TIA
MM’s are working overtime to extract shares without raising the price. Whats it going to take to get this stock into “fair” territory. We are still at the bottom of our range with copper being all the new rage and gold over $2300.
I guess the big boyz have to get theirs first. Nice sleeper stock
Amazing isnt it, 52 week low sitting on the next safe and effective SOC for Alzheimer’s. Gods watching!
It will be very interesting to see who is left holding the bag of shares after this rebalancing of the Russel 2000. There is no other way to get shares in large amounts outside of buying them on the open market.
We will see if Harald Hampel joined the right #WINNING! Team after all. First to market isnt always the best.
Thanks for the reminder Chris.’Quite the ensemble that is being comprised here at little ol Anavex. Many recent Senior roles throwing away their careers by joining a pre revenue biotech at a mere $3.69 a share in a washed up, over committed, near failing hair brained Ceo led company…or do they know something we dont know? Is it that Dr. Missling wasnt “investor” hunting at all these “financial” and scientific conferences but rather “head” hunting? Im sure the that companies cultures become bloated, toxic, stagnant etc so maybe joining a young agile biotech with promising data at becoming the next SOC for many CNS diseases has its appeal?
All I know is Im staying parked regardless of the financial wizards doling out free saving advice, save it!
Appears on the surface that shares are getting harder and harder to shake out. .20 - .75 cent moves. Time to let it rain.
Nice idea Nidan just dont hold your breath. Sorry for the late reply as I didnt see your reply.
Historically did these filings support their findings with full genomic data from a trial in a different disease that correlates 70%? Not saying this would multiply by 10 fold. Like Cresentmotor said, he could of just been overstating the monumental task to prove a point.
Thanks for shedding light cresentmotor. I would only add that I believe they would also be adding genomic findings from the PDD trial as he has mentioned more than once that there is a 70% correlation between the two diseases.
Much heavy lifting and after further thought it was probably this MAA filing that was what put our prior Fda exec. Dr. Fadirian out to pasture. The poor man has carried many filings for us for years on top of his 27 (?) years at the Fda and probably didnt have the umph to sit through the arduous task of putting it all together.
Jhmo
“ managing biometrics activities for 4 oncology compounds' clinical development (model-based strategical designs in drug development,”
This caught my eye from her previous experience. Dr. Missling has repeatedly mentioned we are retracing the road cancer medicines have taken whereas utilizing the bodies own defense mechanism to rid the body upstream of the disease instead of micromanaging treating a symptom(s) of the disease.
Great insight and revolutionary if you ask me.
Im pretty sure I heard him mention it in the conference. His dialect is pretty heavy but I will re listen to it again for a third time and see.
Well said Hosai. Unlike many here Dr. Missling is staying the course, keeping the company funded, and in the “applying for regulatory approval stage” ( paraphrased). This is huge, a 1 million page document with many modules for EMA regulatory approval is a monumental task for a small company. The good part is it sounds like much of it overlaps from agency to agency. This bodes well coupling it with the “phase 4 open label AD trial which is not needed but is helpful in showing safety” ( paraphrased) finishing in July. All good news and yet the price drops.
I cant wait for Dr. Missling to drop the MOAB on the world.
Cheers
Tred
Well, in light of all the trial data to date that has been presented so often that even I can recite it with clarity and ease. Efficacy is as efficacy is as efficacy is….! Its not about the efficacy here, its about approval and REVENUE! If Kun Jin’s presence doesnt give you and others pause as to your disbief thannothing is going to convince you that Anavex has a safe, oral, novel drug for Alzheimer’s that blows away the SOC and worth everybit of 20 billion dollars upon approval.
All that being said, YES there is a conspiracy to suppress the price when the above stands true and we sit at $3.69! Algorithms, spoofing, HFT, weighted indexes, options, naked shorting dark pools, lawsuits, and yes, delay tactics from “Dr’s” on the take. So many ways to hammer a small company until someone gets a wiff of revenue generation.
Woe to you Pharisees and Sagisees, you see and still you do not believe!
What are the chances that one of the “peer reviewers” is communicating to “friends” that the paper is close to completion and looks very promising? Just sayin as BP’s tentacles run deep in research grants. More than one way to cause a delay in bring a novel drug to market.
Money dammit!!! All we want is more and more MONEY!! Arent you aware its not about patients getting better or approval just give the hungry market more gratification through profits!!
All sarcasm of course but true unfortunately.
“If they are committed then I think the medical staff can order whatever meds they want, no?”
As long as they dont delay the trial from those damn covid requirements. They probably still have the i patients walking round with masks.
Ohh just the thought!
Good assessment of the conference Skitahoe. I agree with it and might add that they are not waiting for approval before thinking a out commercialization. I find it in stark contrast of many negative posters here the fact that a company who is so crooked in producing illusionary trials data has spent much of their last 3-4 presentations highlighting the commercialization aspect “ ahead” of approval. He even mentioned utilizing Amazon this time around , which I had envisioned some months ago, as a reliable source for delivery. This drug, its partnership (s), and its access to market is going to revolutionize the way medicine is practiced in the not too distant future.
Along those lines too he is very upbeat about the Fda and their new endpoint acceptance qualification for AD. Couldnt happen at a better time, for a better drug, for a top notch company.
I say pound sand to all those who are looking for tree branches high enough with ropes in their hands. I also had a vision/reflection of a time long ago when another person was trying to share something revolutionary with the world. He also went to another group instead of the first group for acceptance and still, the powers to be were overly concerned about their wealth, status, and power so much so they had Him killed. The more things change the more they stay the same.
Blessings
Tred
He is not talking to anyone on this board CM so your reply is futile. His dog whistle is heard by his followers.
Volume and wealth transfer will trend with our being graced by the posers to be. Trust me, they are lurking.
Todays presentation tells me all I need to know. I hope Dr M launches a surprise here one day soon, he is due some credit.